Orexigen Therapeutics (OREX) Receives Daily News Impact Rating of 0.11
News articles about Orexigen Therapeutics (NASDAQ:OREX) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Orexigen Therapeutics earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 47.4849179032692 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Several research analysts have commented on OREX shares. Zacks Investment Research raised shares of Orexigen Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a report on Monday, August 14th. ValuEngine downgraded shares of Orexigen Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.
Shares of Orexigen Therapeutics (OREX) traded up $0.04 during trading hours on Friday, reaching $1.66. 36,471 shares of the company’s stock traded hands, compared to its average volume of 154,264. The company has a quick ratio of 1.71, a current ratio of 2.00 and a debt-to-equity ratio of -2.75. Orexigen Therapeutics has a 1 year low of $1.55 and a 1 year high of $5.70.
Orexigen Therapeutics (NASDAQ:OREX) last announced its quarterly earnings results on Monday, November 13th. The biopharmaceutical company reported ($1.35) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.13) by $0.78. Orexigen Therapeutics had a negative net margin of 192.65% and a negative return on equity of 824.15%. The firm had revenue of $18.90 million during the quarter, compared to the consensus estimate of $24.20 million. During the same period last year, the firm earned $1.12 EPS. The business’s quarterly revenue was up 170.0% compared to the same quarter last year. equities analysts expect that Orexigen Therapeutics will post -10.08 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Orexigen Therapeutics (OREX) Receives Daily News Impact Rating of 0.11” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.watchlistnews.com/orexigen-therapeutics-orex-receives-daily-news-impact-rating-of-0-11/1726267.html.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.
Receive News & Ratings for Orexigen Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orexigen Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.